| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:44 UTC |
|---|
| HMDB ID | HMDB0014775 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Astemizole |
|---|
| Description | Astemizole, also known as astemison or hismanal, belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds). Astemizole is a very strong basic compound (based on its pKa). In humans, astemizole is involved in astemizole h1-antihistamine action. Astemizole is a potentially toxic compound. A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-amino group at the 4-position. |
|---|
| Structure | COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1 InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31) |
|---|
| Synonyms | | Value | Source |
|---|
| 1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole | ChEBI | | 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole | ChEBI | | Astemison | ChEBI | | Astemizol | ChEBI | | Astemizolum | ChEBI | | Hismanal | Kegg | | Alonga brand OF astemizole | HMDB | | Astemizole alacan brand | HMDB | | Astemizole byk brand | HMDB | | Astemizole diba brand | HMDB | | Astemizole esteve brand | HMDB | | Astemizole senosiain brand | HMDB | | Astemizole ratiopharm brand | HMDB | | Esteve brand OF astemizole | HMDB | | Fustery brand OF astemizole | HMDB | | Histaminos | HMDB | | ICN brand OF astemizole | HMDB | | Rifedot | HMDB | | Rimbol | HMDB | | Senosiain brand OF astemizole | HMDB | | Smaller brand OF astemizole | HMDB | | Alonga, astemizol | HMDB | | Astemina | HMDB | | Astemizol alonga | HMDB | | Astemizole icn brand | HMDB | | Astemizole medinsa brand | HMDB | | Astemizole merck brand | HMDB | | Astemizole smaller brand | HMDB | | Astemizole urbion brand | HMDB | | Astemizole vita brand | HMDB | | Astesen | HMDB | | Hubermizol | HMDB | | Laridal | HMDB | | Lesvi brand OF astemizole | HMDB | | Reig jofre brand OF astemizole | HMDB | | Romadin | HMDB | | Urbion brand OF astemizole | HMDB | | Ratiopharm brand OF astemizole | HMDB | | Ratiopharm, astemizol | HMDB | | Astemizole alonga brand | HMDB | | Astemizole elfar brand | HMDB | | Astemizole fustery brand | HMDB | | Astemizole janssen brand | HMDB | | Astemizole lesvi brand | HMDB | | Astemizole mcneil brand | HMDB | | Astemizole septa brand | HMDB | | Byk brand OF astemizole | HMDB | | Diba brand OF astemizole | HMDB | | Elfar brand OF astemizole | HMDB | | Emdar | HMDB | | Fustermizol | HMDB | | McNeil brand OF astemizole | HMDB | | Merck brand OF astemizole | HMDB | | Simprox | HMDB | | Urdrim | HMDB | | Alacan brand OF astemizole | HMDB | | Alermizol | HMDB | | Astemizol ratiopharm | HMDB | | Esmacen | HMDB | | Janssen brand OF astemizole | HMDB | | Medinsa brand OF astemizole | HMDB | | Paralergin | HMDB | | Retolen | HMDB | | Septa brand OF astemizole | HMDB | | Vita brand OF astemizole | HMDB |
|
|---|
| Chemical Formula | C28H31FN4O |
|---|
| Average Molecular Weight | 458.5703 |
|---|
| Monoisotopic Molecular Weight | 458.248189839 |
|---|
| IUPAC Name | 1-[(4-fluorophenyl)methyl]-N-{1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl}-1H-1,3-benzodiazol-2-amine |
|---|
| Traditional Name | astemizole |
|---|
| CAS Registry Number | 68844-77-9 |
|---|
| SMILES | COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1 |
|---|
| InChI Identifier | InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31) |
|---|
| InChI Key | GXDALQBWZGODGZ-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds). |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzimidazoles |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Benzimidazoles |
|---|
| Alternative Parents | |
|---|
| Substituents | - Benzimidazole
- Phenethylamine
- Anisole
- Phenoxy compound
- Phenol ether
- Methoxybenzene
- Alkyl aryl ether
- Fluorobenzene
- Halobenzene
- Aralkylamine
- Piperidine
- Benzenoid
- Aryl fluoride
- Aryl halide
- N-substituted imidazole
- Monocyclic benzene moiety
- Heteroaromatic compound
- Azole
- Imidazole
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Ether
- Hydrocarbon derivative
- Amine
- Organic oxygen compound
- Organic nitrogen compound
- Organohalogen compound
- Organofluoride
- Organonitrogen compound
- Organooxygen compound
- Organopnictogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 149.1 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.0012 g/L | Not Available | | LogP | 5.8 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.1 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.702 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.69 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 73.1 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1226.4 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 205.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 214.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 191.3 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 132.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 452.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 469.3 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 639.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 905.6 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 415.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 920.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 263.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 342.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 405.6 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 442.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 7.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Astemizole,1TMS,isomer #1 | COC1=CC=C(CCN2CCC(N(C3=NC4=CC=CC=C4N3CC3=CC=C(F)C=C3)[Si](C)(C)C)CC2)C=C1 | 3820.7 | Semi standard non polar | 33892256 | | Astemizole,1TMS,isomer #1 | COC1=CC=C(CCN2CCC(N(C3=NC4=CC=CC=C4N3CC3=CC=C(F)C=C3)[Si](C)(C)C)CC2)C=C1 | 3431.0 | Standard non polar | 33892256 | | Astemizole,1TMS,isomer #1 | COC1=CC=C(CCN2CCC(N(C3=NC4=CC=CC=C4N3CC3=CC=C(F)C=C3)[Si](C)(C)C)CC2)C=C1 | 4880.0 | Standard polar | 33892256 | | Astemizole,1TBDMS,isomer #1 | COC1=CC=C(CCN2CCC(N(C3=NC4=CC=CC=C4N3CC3=CC=C(F)C=C3)[Si](C)(C)C(C)(C)C)CC2)C=C1 | 4020.1 | Semi standard non polar | 33892256 | | Astemizole,1TBDMS,isomer #1 | COC1=CC=C(CCN2CCC(N(C3=NC4=CC=CC=C4N3CC3=CC=C(F)C=C3)[Si](C)(C)C(C)(C)C)CC2)C=C1 | 3588.7 | Standard non polar | 33892256 | | Astemizole,1TBDMS,isomer #1 | COC1=CC=C(CCN2CCC(N(C3=NC4=CC=CC=C4N3CC3=CC=C(F)C=C3)[Si](C)(C)C(C)(C)C)CC2)C=C1 | 4887.4 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Astemizole GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4i-1922000000-2742ecd8a8c6af4db428 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Astemizole GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Astemizole 10V, Positive-QTOF | splash10-0a4i-0110900000-7c47b2813568251daf1e | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Astemizole 20V, Positive-QTOF | splash10-052r-1947600000-b67040fd618da0f36a6a | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Astemizole 40V, Positive-QTOF | splash10-0016-2940000000-e1a0cda3eae5d6bc1cf6 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Astemizole 10V, Negative-QTOF | splash10-0a4i-0010900000-e80e4e306be153aeab7c | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Astemizole 20V, Negative-QTOF | splash10-0abc-0145900000-d00ee25e0101b4beb25a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Astemizole 40V, Negative-QTOF | splash10-01qd-3893000000-dae89e0c7d17da3e1c78 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Astemizole 10V, Positive-QTOF | splash10-0a4i-0000900000-416ae1ceda818e4c922c | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Astemizole 20V, Positive-QTOF | splash10-0a4i-0200900000-3d85252f27ae2ba0258e | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Astemizole 40V, Positive-QTOF | splash10-0570-1624900000-4ea28e09b60d7c3b3618 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Astemizole 10V, Negative-QTOF | splash10-0a4i-0000900000-afe434091fa2787a5ed5 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Astemizole 20V, Negative-QTOF | splash10-0a4i-0000900000-142d31f8c19fb007efb7 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Astemizole 40V, Negative-QTOF | splash10-0a59-0794800000-0f835aeecbc38bc493f2 | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Wang X, Hockerman GH, Green HW 3rd, Babbs CF, Mohammad SI, Gerrard D, Latour MA, London B, Hannon KM, Pond AL: Merg1a K+ channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway. FASEB J. 2006 Jul;20(9):1531-3. Epub 2006 May 24. [PubMed:16723379 ]
- Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr: A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol. 2006 Aug;2(8):415-6. Epub 2006 Jul 2. [PubMed:16816845 ]
|
|---|